Last reviewed · How we verify
US Sourced Avastin®
At a glance
| Generic name | US Sourced Avastin® |
|---|---|
| Sponsor | Cipla BioTec Pvt. Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. (PHASE1)
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects (PHASE1)
- Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects (PHASE1)
- Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects (PHASE1)
- PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US Sourced Avastin® CI brief — competitive landscape report
- US Sourced Avastin® updates RSS · CI watch RSS
- Cipla BioTec Pvt. Ltd. portfolio CI